# Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management and makes the authorization for pharmacists to perform such management permanent

**Bill ID:** A9702
**Session:** 2024
**Sponsor:** Rebecca Seawright
**Status:** In Assembly Committee
**PDF:** [A9702 PDF](https://legislation.nysenate.gov/pdf/bills/2024/A9702)

## Summary

Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management; makes the authorization for pharmacists to perform such management permanent.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  9702
 
  I N  A S S E M B L Y
 
  April 3, 2024
  ___________
 
 Introduced by M. of A. SEAWRIGHT, STIRPE, LUPARDO, BUTTENSCHON, FORREST,
  McDONALD  --  read once and referred to the Committee on Higher Educa-
  tion
 
 AN ACT to amend the education law, in relation to including nurse  prac-
  titioners as a provider of services for purposes of collaborative drug
  therapy management; and to amend chapter 21 of the laws of 2011 amend-
  ing  the  education law relating to authorizing pharmacists to perform
  collaborative drug  therapy  management  with  physicians  in  certain
  settings,  in  relation to making the authorization for pharmacists to
  perform collaborative drug therapy management permanent
 
  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section  1. Section 6801-a of the education law, as amended by chapter
 238 of the laws of 2015, is amended to read as follows:
  ยง  6801-a.  Collaborative  drug  therapy  management  [demonstration
 program].  1.  As used in this section, the following terms shall have
 the following meanings:
  a. "Board" shall mean the state board of pharmacy  as  established  by
 section sixty-eight hundred four of this article.
  b. "Clinical services" shall mean the collection and interpretation of
 patient  data  for  the  purpose of initiating, modifying and monitoring
 drug therapy  with  associated  accountability  and  responsibility  for
 outcomes in a direct patient care setting.
  c.  "Collaborative drug therapy management" shall mean the performance
 of clinical services by a pharmacist relating to the review,  evaluation
 and  management  of drug therapy to a patient, who is being treated by a
 physician OR NURSE PRACTITIONER for a  specific  disease  or  associated
 disease  states, in accordance with a written agreement or protocol with
 a voluntarily participating  physician  OR  NURSE  PRACTITIONER  and  in
 accordance with the policies, procedures, and protocols of the facility.
 Such  agreement  or  protocol  as entered into by the physician OR NURSE
 PRACTITIONER and a pharmacist, may include, and shall be limited to:
  (i) adjusting or managing a drug regimen of a patient, pursuant  to  a
 patient  specific  order  or protocol made by the patient's physician OR
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD00382-01-3
 A. 9702  2
 
 NURSE PRACTITIONER, which may include adjusting drug strength, frequency
 of administration or route of administration. Adjusting the drug regimen
 shall not include substituting  or  selecting  a  different  drug  which
 differs  from  that  initially  prescribed by the patient's physician OR
 NURSE PRACTITIONER unless such substitution is expressly  authorized  in
 the written order or protocol. The pharmacist shall be required to imme-
 diately  document  in  the  patient record changes made to the patient's
 drug therapy and shall use any reasonable means or method established by
 the facility to notify the patient's other treating physicians OR  NURSE
 PRACTITIONERS  with  whom he or she does not have a written agreement or
 protocol regarding such changes. The patient's physician OR NURSE  PRAC-
 TITIONER  may prohibit, by written instruction, any adjustment or change
 in the patient's drug regimen by the pharmacist;
  (ii) evaluating and, only if specifically authorized by  the  protocol
 and  only  to the extent necessary to discharge the responsibilities set
 forth in this section, ordering disease state laboratory  tests  related
 to the drug therapy management for the specific disease or disease state
 specified within the written agreement or protocol; and
  (iii)  only  if  specifically  authorized  by the written agreement or
 protocol and only to the extent necessary to discharge the  responsibil-
 ities  set forth in this section, ordering or performing routine patient
 monitoring functions as may be necessary in the drug therapy management,
 including the collecting and reviewing of patient histories, and  order-
 ing or checking patient vital signs, including pulse, temperature, blood
 pressure and respiration.
  d.  "Facility" shall mean: (i) a [teaching hospital or general] hospi-
 tal, [including any diagnostic center, treatment  center,  or  hospital-
 based  outpatient  department]  as defined in SUBDIVISION ONE OF section
 twenty-eight hundred one of the public health law;  or  (ii)  a  nursing
 home  with  an  on-site  pharmacy  staffed  by  a  licensed  pharmacist;
 provided, however, for the purposes of this section the term  "facility"
 shall  not  include  dental  clinics,  dental  dispensaries, residential
 health care facilities and rehabilitation centers.
  [For the purposes of this section, a "teaching hospital" shall mean  a
 hospital  licensed pursuant to article twenty-eight of the public health
 law that is eligible to receive  direct  or  indirect  graduate  medical
 education payments pursuant to article twenty-eight of the public health
 law.]  IN ADDITION, A FACILITY MAY ALSO INCLUDE UP TO FIFTEEN COMMUNITY-
 PRACTICE SITES, SELECTED BY THE  DEPARTMENT  IN  CONSULTATION  WITH  THE
 DEPARTMENT  OF HEALTH, WHERE PHARMACISTS AND PHYSICIANS OR NURSE PRACTI-
 TIONERS MAY PROPOSE TO ENTER INTO COLLABORATIVE  ARRANGEMENTS,  PURSUANT
 TO  THE  PROVISIONS  OF THIS SECTION. SUCH SITES SHALL BE SELECTED BASED
 UPON A REVIEW OF APPLICATIONS SUBMITTED TO THE DEPARTMENT BY SUCH  PHAR-
 MACISTS  AND  PHYSICIANS  OR NURSE PRACTITIONERS, WHICH DEMONSTRATE THAT
 THE APPLICANTS CAN SATISFY THE REQUIREMENTS OF THIS SECTION.
  e. "Physician" OR "NURSE PRACTITIONER" shall  mean  the  physician  OR
 NURSE PRACTITIONER selected by or assigned to a patient, who has primary
 responsibility for the treatment and care of the patient for the disease
 and  associated disease states that are the subject of the collaborative
 drug therapy management.
  f. "Written agreement or protocol"  shall  mean  a  written  document,
 pursuant to and consistent with any applicable state or federal require-
 ments,  that  addresses  a specific disease or associated disease states
 and that describes the nature and scope of  collaborative  drug  therapy
 management  to  be  undertaken by the pharmacists, in collaboration with
 A. 9702  3
 
 the participating physician OR NURSE PRACTITIONER in accordance with the
 provisions of this section.
  2.  a. A pharmacist who meets the experience requirements of paragraph
 b of this subdivision and who is EITHER employed by or otherwise  affil-
 iated with a facility OR IS PARTICIPATING WITH A COMMUNITY-PRACTICE SITE
 SELECTED  PURSUANT  TO  PARAGRAPH  D  OF SUBDIVISION ONE OF THIS SECTION
 shall be permitted to enter into a written agreement or protocol with  a
 physician  OR  NURSE PRACTITIONER authorizing collaborative drug therapy
 management, subject to the limitations set forth in this section, within
 the scope of such employment [or], affiliation OR PARTICIPATION.
  b. A participating pharmacist must:
  (i)(A) have been awarded either a master of science in clinical  phar-
 macy or a doctor of pharmacy degree;
  (B) maintain a current unrestricted license; and
  (C) have a minimum of two years experience, of which at least one year
 of such experience shall include clinical experience in a health facili-
 ty,  which  involves consultation with physicians OR NURSE PRACTITIONERS
 with respect to drug therapy and may include a residency at  a  facility
 involving such consultation; or
  (ii)(A) have been awarded a bachelor of science in pharmacy;
  (B) maintain a current unrestricted license; and
  (C) within the last seven years, have a minimum of three years experi-
 ence,  of which at least one year of such experience shall include clin-
 ical experience in a health facility, which involves  consultation  with
 physicians  OR  NURSE PRACTITIONERS with respect to drug therapy and may
 include a residency at a facility involving such consultation; and
  (iii) meet any additional education, experience, or other requirements
 set forth by the department in consultation with the board.
  c. Notwithstanding any provision of law, nothing in this section shall
 prohibit a licensed pharmacist from engaging in clinical services  asso-
 ciated  with  collaborative  drug  therapy  management, in order to gain
 experience necessary to qualify under clause (C) of subparagraph (i)  or
 (ii)  of paragraph b of this subdivision, provided that such practice is
 under the supervision of a pharmacist that currently  meets  the  refer-
 enced  requirement, and that such practice is authorized under the writ-
 ten agreement or protocol with the physician OR NURSE PRACTITIONER.
  d. Notwithstanding any provision of this section, nothing herein shall
 authorize the pharmacist to diagnose disease. In the event that a treat-
 ing physician OR NURSE PRACTITIONER may disagree with  the  exercise  of
 professional  judgment  by  a  pharmacist,  the judgment of the treating
 physician OR NURSE PRACTITIONER shall prevail.
  3. The physician OR NURSE PRACTITIONER who is a  party  to  a  written
 agreement  or protocol authorizing collaborative drug therapy management
 shall be employed by or otherwise affiliated with the same facility with
 which the pharmacist is also employed or affiliated.
  4. The existence of a written agreement or protocol  on  collaborative
 drug therapy management and the patient's right to choose to not partic-
 ipate in collaborative drug therapy management shall be disclosed to any
 patient  who  is  eligible to receive collaborative drug therapy manage-
 ment. Collaborative drug therapy management shall not be utilized unless
 the patient or the  patient's  authorized  representative  consents,  in
 writing,  to such management. If the patient or the patient's authorized
 representative consents, it shall be  noted  on  the  patient's  medical
 record.  If  the  patient or the patient's authorized representative who
 consented to collaborative drug therapy management chooses to no  longer
 participate  in  such  management, at any time, it shall be noted on the
 A. 9702  4
 
 patient's medical record. In addition,  the  existence  of  the  written
 agreement or protocol and the patient's consent to such management shall
 be  disclosed  to  the patient's primary physician OR NURSE PRACTITIONER
 and  any  other  treating  physician OR NURSE PRACTITIONER or healthcare
 provider.
  5. Participation in a written agreement or protocol authorizing colla-
 borative drug therapy management shall be  voluntary,  and  no  patient,
 physician  OR  NURSE  PRACTITIONER,  pharmacist,  or  facility  shall be
 required to participate.
  6. Nothing in this section shall be deemed to limit the scope of prac-
 tice of pharmacy nor be deemed to limit the authority of pharmacists and
 physicians OR NURSE PRACTITIONERS to  engage  in  medication  management
 prior to the effective date of this section and to the extent authorized
 by law.
  ยง  2.  Section 5 of chapter 21 of the laws of 2011 amending the educa-
 tion law relating to authorizing pharmacists  to  perform  collaborative
 drug  therapy management with physicians in certain settings, as amended
 by section 5 of part CC of chapter 57 of the laws of 2022, is amended to
 read as follows:
  ยง 5. This act shall take effect on the one hundred twentieth day after
 it shall have become a law[, provided, however, that the  provisions  of
 sections  two,  three,  and  four of this act shall expire and be deemed
 repealed July 1, 2024]; provided, however, that the amendments to subdi-
 vision 1 of section 6801 of the education law made  by  section  one  of
 this act shall be subject to the expiration and reversion of such subdi-
 vision  pursuant  to  section 8 of chapter 563 of the laws of 2008, when
 upon such date the provisions of section one-a of this  act  shall  take
 effect;  provided,  further,  that  effective immediately, the addition,
 amendment and/or repeal of any rule  or  regulation  necessary  for  the
 implementation  of  this  act  on  its effective date are authorized and
 directed to be made and completed on or before such effective date.
  ยง 3. This act shall take effect on the one hundred twentieth day after
 it shall have become a law. Effective immediately, the addition,  amend-
 ment and/or repeal of any rule or regulation necessary for the implemen-
 tation  of  this act on its effective date are authorized to be made and
 completed on or before such effective date.